Staci Shepard
Family Medicine · Waynesville, NCNPI 1558771584
Payments from drug & device makers
Across 197 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$787
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$469
- Novo Nordisk$350
- GSK$325
- AstraZeneca$248
- Pfizer$228
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,073100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $787 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $469 |
| Novo Nordisk | 22 | $350 |
| GSK | 16 | $325 |
| AstraZeneca | 17 | $248 |
| Pfizer | 13 | $228 |
| Amgen | 10 | $203 |
| Axsome Therapeutics, Inc. | 8 | $187 |
| Lilly USA, LLC | 10 | $179 |
| Astellas Pharma US Inc | 3 | $167 |
| Abbott | 6 | $139 |
| Vanda Pharmaceuticals Inc. | 4 | $113 |
| Bayer | 5 | $85 |
| Teva Pharmaceuticals USA, Inc. | 4 | $64 |
| Exact Sciences | 4 | $63 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $55 |
| Johnson & Johnson | 3 | $51 |
| Amarin Pharma, Inc. | 3 | $43 |
| Novartis | 2 | $41 |
| Corium, LLC | 2 | $39 |
| Insulet Corporation | 1 | $31 |
| Stryker | 1 | $27 |
| Gilead | 2 | $24 |
| Medtronic | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Radius Health, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Globus Medical | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$364
- Veozah$125
- TRELEGY ELLIPTA$106
How this compares
$4,084 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $131,377 |
| FarxigaDapagliflozin Propanediol | 118 | $120,205 |
| EliquisApixaban | 97 | $102,722 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 94 | $93,259 |
| MounjaroTirzepatide | 38 | $42,216 |
| XareltoRivaroxaban | 45 | $36,454 |
| TrulicityDulaglutide | 37 | $33,606 |
| JardianceEmpagliflozin | 29 | $30,845 |
| VascepaIcosapent Ethyl | 53 | $23,568 |
| VraylarCariprazine Hcl | 13 | $17,681 |
| Aimovig AutoinjectorErenumab-Aooe | 22 | $17,296 |
| Spiriva HandihalerTiotropium Bromide | 22 | $16,145 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $14,094 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $13,177 |
| KerendiaFinerenone | 12 | $12,820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $350 | $131,377118 claims |
| AstraZenecaFarxiga, Symbicort | $248 | $124,264130 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $325 | $118,590145 claims |
| PfizerEliquis | $228 | $102,72297 claims |
| Lilly USA, LLCMounjaro, Trulicity | $179 | $75,82275 claims |
| Johnson & JohnsonXarelto | $51 | $36,45445 claims |
| AbbVieVraylar, Synthroid | $787 | $19,96842 claims |
| BayerKerendia | $85 | $12,82012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Waynesville
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.